IndiaTickerLatest filing: Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Bafna Pharmaceuticals Limited
ObservedCompany dossier
Bafna Pharmaceuticals
NSE:BAFNAPH · ISIN INE878I01022
- Close
- Unavailable Date unavailable
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Bafna Pharmaceuticals
Overview
Evidence state
Coverage in progressCompany record at a glance
Latest reported period: 31 Dec 2024 · revenue ₹33.2 Cr · PAT ₹0.9 Cr.
Exchange XBRLLatest ownership: promoter group 75.00% and public 25.00% as of 30 Jun 2026.
Exchange XBRLLatest rating action: Bafna Pharmaceuticals Limited: Ratings reaffirmed; rated amount enhanced; outlook revised to Positive from Stable
Archived reportMaterial events
Open timeline →What changed recently
Observed
Source filing Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Bafna Pharmaceuticals Limited
NSE · exchange filing
Observed
Source filing Bafna Pharmaceuticals Ltd - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
BSE · exchange filing
Observed
Source filing Disclosure under SEBI Takeover Regulations - Bafna Pharmaceuticals Limited
NSE · exchange filing
Observed
Source filing Trading Window - Bafna Pharmaceuticals Limited
NSE · exchange filing
Reported financials
Full financials →31 Dec 2024
- Revenue from operations
- ₹33.2 Cr
- Profit after tax
- ₹0.9 Cr
- EPS
- ₹0.40
Observed NSE structured filing · Non-Consolidated
Ownership
Full shareholding →30 Jun 2026
- Promoter group
- 75.00%
- Public
- 25.00%
- Employee trust
- 0.00%
Observed NSE shareholding XBRL